Dr. Suzanne Merrill

Yeah, no, I think it's an important kind of topic to bring up. And it's certainly one of discussion and one of preference. But I will tell you that when this optical imaging agent rolled out, it was FDA approved in 2010. And so it's been around for quite some time.

Yeah, no, I think it's an important kind of topic to bring up. And it's certainly one of discussion and one of preference. But I will tell you that when this optical imaging agent rolled out, it was FDA approved in 2010. And so it's been around for quite some time.

And initially, we were using it really in patients that we knew already had a diagnosis of CIS, where it really has shown to detect that cancer, actually showing ultimately that it detects it, just to give you some hard data here, detects CIS tumors were found in 34.6%. patients compared to, for example, white light. The CIS tumors were only found in blue light up to 34.6% of the time.

And initially, we were using it really in patients that we knew already had a diagnosis of CIS, where it really has shown to detect that cancer, actually showing ultimately that it detects it, just to give you some hard data here, detects CIS tumors were found in 34.6%. patients compared to, for example, white light. The CIS tumors were only found in blue light up to 34.6% of the time.

And initially, we were using it really in patients that we knew already had a diagnosis of CIS, where it really has shown to detect that cancer, actually showing ultimately that it detects it, just to give you some hard data here, detects CIS tumors were found in 34.6%. patients compared to, for example, white light. The CIS tumors were only found in blue light up to 34.6% of the time.

And so initially people thought, well, maybe I should only use it for CIS patients. And ultimately, right, we only know a patient has CIS after that first TURBT. And so people would use it in that sort of situation. It was also felt to be a good use in people that had that positive cytology, but that white light surveillance cystoscopy didn't show anything abnormal.

And so initially people thought, well, maybe I should only use it for CIS patients. And ultimately, right, we only know a patient has CIS after that first TURBT. And so people would use it in that sort of situation. It was also felt to be a good use in people that had that positive cytology, but that white light surveillance cystoscopy didn't show anything abnormal.

And so initially people thought, well, maybe I should only use it for CIS patients. And ultimately, right, we only know a patient has CIS after that first TURBT. And so people would use it in that sort of situation. It was also felt to be a good use in people that had that positive cytology, but that white light surveillance cystoscopy didn't show anything abnormal.

And so you could use it there to see if we could see anything better under blue light illuminescence. But really, as we've used this technology more and more, we're finding that it really has more widespread applications. And it can be used for any resection, for any low-grade, high-grade patient or stage of disease.

And so you could use it there to see if we could see anything better under blue light illuminescence. But really, as we've used this technology more and more, we're finding that it really has more widespread applications. And it can be used for any resection, for any low-grade, high-grade patient or stage of disease.

And so you could use it there to see if we could see anything better under blue light illuminescence. But really, as we've used this technology more and more, we're finding that it really has more widespread applications. And it can be used for any resection, for any low-grade, high-grade patient or stage of disease.

I will tell you that when I don't think about using this is in your high volume tumor patients. So where you've gone in there cystoscopically, you know, the first time after the workup and there's just tumor everywhere. You have a hard time seeing normal urethelial walls. It's very hard to navigate kind of around the bladder. that is probably not a great time to use this technology.

I will tell you that when I don't think about using this is in your high volume tumor patients. So where you've gone in there cystoscopically, you know, the first time after the workup and there's just tumor everywhere. You have a hard time seeing normal urethelial walls. It's very hard to navigate kind of around the bladder. that is probably not a great time to use this technology.

I will tell you that when I don't think about using this is in your high volume tumor patients. So where you've gone in there cystoscopically, you know, the first time after the workup and there's just tumor everywhere. You have a hard time seeing normal urethelial walls. It's very hard to navigate kind of around the bladder. that is probably not a great time to use this technology.

But I can tell you, though, using that technology on that patient for the second resection is a great use to make sure that you've gotten all the tumor out of there, that you can see kind of your margins of resection. You know, I think we've all felt, and I'm sure you can agree, Suzette, that we do not do as good of a job with TRBTs as we think we do, right?

But I can tell you, though, using that technology on that patient for the second resection is a great use to make sure that you've gotten all the tumor out of there, that you can see kind of your margins of resection. You know, I think we've all felt, and I'm sure you can agree, Suzette, that we do not do as good of a job with TRBTs as we think we do, right?

But I can tell you, though, using that technology on that patient for the second resection is a great use to make sure that you've gotten all the tumor out of there, that you can see kind of your margins of resection. You know, I think we've all felt, and I'm sure you can agree, Suzette, that we do not do as good of a job with TRBTs as we think we do, right?

We train our residents, you know, very early on with doing TRBTs. Obviously, this is a cornerstone of urology. They need to know how to do them. But many times when we're doing TRBTs, we're with a junior resident, for example. This is kind of the junior resident case.

We train our residents, you know, very early on with doing TRBTs. Obviously, this is a cornerstone of urology. They need to know how to do them. But many times when we're doing TRBTs, we're with a junior resident, for example. This is kind of the junior resident case.

We train our residents, you know, very early on with doing TRBTs. Obviously, this is a cornerstone of urology. They need to know how to do them. But many times when we're doing TRBTs, we're with a junior resident, for example. This is kind of the junior resident case.